Literature DB >> 22370600

A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006.

Charlotte Gerd Hannibal1, Russell Vang, Jette Junge, Anette Kjaerbye-Thygesen, Robert J Kurman, Susanne K Kjaer.   

Abstract

OBJECTIVE: To evaluate the prognostic significance of histologic grade on survival of ovarian serous cancer in Denmark during nearly 30 years.
METHODS: Using the nationwide Danish Pathology Data Bank, we evaluated 4317 women with ovarian serous carcinoma in 1978-2006. All pathology reports were scrutinized and tumors classified as either low-grade serous carcinomas (LGSC) or high-grade serous carcinomas (HGSC). Tumors in which the original pathology reports were described as well-differentiated were classified as LGSC, and those that were described as moderately or poorly differentiated were classified as HGSC. We obtained histologic slides from the pathology departments for women with a diagnosis of well-differentiated serous carcinoma during 1997-2006, which were then reviewed by expert gynecologic pathologists. Data were analyzed using Kaplan-Meier methods and Cox proportional hazards regression analysis with follow-up through June 2009.
RESULTS: Women with HGSC had a significantly increased risk of dying (HR=1.9; 95% CI: 1.6-2.3) compared with women with LGSC while adjusting for age and stage. Expert review of 171 women originally classified as well-differentiated in 1997-2006 were interpreted as LGSC in 30% of cases, whereas 12% were interpreted as HGSC and 50% as serous borderline ovarian tumors (SBT). Compared with women with confirmed LGSC, women with SBT at review had a significantly lower risk of dying (HR=0.5; 95% CI: 0.22-0.99), and women with HGSC at review had a non-significantly increased risk of dying (HR=1.6; 95% CI: 0.7-3.4).
CONCLUSIONS: A binary grading system is a significant predictor of survival for ovarian serous carcinoma.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22370600      PMCID: PMC3358352          DOI: 10.1016/j.ygyno.2012.02.028

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  35 in total

1.  Reproducibility and prognostic value of histologic type and grade in early epithelial ovarian cancer.

Authors:  K. Bertelsen; B. Hølund; E. Andersen
Journal:  Int J Gynecol Cancer       Date:  1993-03       Impact factor: 3.437

2.  Long-term oncological outcomes of ovarian serous carcinomas with psammoma bodies: a novel insight into the molecular pathogenesis of ovarian epithelial carcinoma.

Authors:  Takeshi Motohara; Hironori Tashiro; Yo Miyahara; Isao Sakaguchi; Hideyuki Ohtake; Hidetaka Katabuchi
Journal:  Cancer Sci       Date:  2010-03-10       Impact factor: 6.716

Review 3.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Hum Pathol       Date:  2011-07       Impact factor: 3.466

4.  Testing the validity of a prognostic classification in patients with surgically optimal ovarian carcinoma: a 15-year review.

Authors:  M.S. Carey; A.J. Dembo; J.E. Simm; A.W. Fyles; T. Treger; R.S. Bush
Journal:  Int J Gynecol Cancer       Date:  1993-01       Impact factor: 3.437

5.  Prognostic factors and adjuvant treatment in early epithelial ovarian cancer.

Authors:  K. Bertelsen; B. Hølund; J.E. Andersen; K. Nielsen; I. Strøyer; P. Ladehoff
Journal:  Int J Gynecol Cancer       Date:  1993-07       Impact factor: 3.437

6.  Quantitative prognostic features in FIGO I ovarian cancer patients without postoperative treatment.

Authors:  J Brugghe; J P Baak; E Wiltshaw; M Brinkhuis; G A Meijer; C Fisher
Journal:  Gynecol Oncol       Date:  1998-01       Impact factor: 5.482

7.  Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument.

Authors:  C Tropé; J Kaern; T Hogberg; V Abeler; B Hagen; G Kristensen; M Onsrud; E Pettersen; P Rosenberg; R Sandvei; K Sundfor; I Vergote
Journal:  Ann Oncol       Date:  2000-03       Impact factor: 32.976

Review 8.  Gynecologic cancers.

Authors:  Amy R Blair; Cheyanne M Casas
Journal:  Prim Care       Date:  2009-03       Impact factor: 2.907

Review 9.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

Authors:  Ie-Ming Shih; Robert J Kurman
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

10.  Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features--problems involved in the architectural grading system.

Authors:  Y Shimizu; S Kamoi; S Amada; K Hasumi; F Akiyama; S G Silverberg
Journal:  Gynecol Oncol       Date:  1998-07       Impact factor: 5.482

View more
  10 in total

1.  MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma.

Authors:  Xiaotang Yu; Xinchen Zhang; Tie Bi; Yanfang Ding; Jinyao Zhao; Chang Wang; Tingting Jia; Dan Han; Gordon Guo; Bo Wang; Jiyong Jiang; Shiying Cui
Journal:  Tumour Biol       Date:  2013-07-09

2.  A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002: centralized pathology review and overall survival compared with the general population.

Authors:  Charlotte Gerd Hannibal; Russell Vang; Jette Junge; Kirsten Frederiksen; Anette Kjaerbye-Thygesen; Klaus Kaae Andersen; Ann Tabor; Robert J Kurman; Susanne K Kjaer
Journal:  Gynecol Oncol       Date:  2014-06-10       Impact factor: 5.482

3.  Analysis of Morbidity, Mortality and Survival Pattern Following Surgery for Borderline Ovarian and Malignant Ovarian Tumour in Tertiary Care Centre.

Authors:  Shanmugasundaram Gouthaman; Snehalatha Kothari; Jaya Vijayaraghavan; Ravi Shankar Pitani
Journal:  J Obstet Gynaecol India       Date:  2021-02-19

4.  Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.

Authors:  Björn Nodin; Nooreldin Zendehrokh; Magnus Sundström; Karin Jirström
Journal:  Diagn Pathol       Date:  2013-06-25       Impact factor: 2.644

5.  A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology.

Authors:  Ming Chen; Ying Jin; Yalan Bi; Jie Yin; Yongxue Wang; Lingya Pan
Journal:  Onco Targets Ther       Date:  2014-10-16       Impact factor: 4.147

6.  Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC).

Authors:  Zheng Feng; Hao Wen; Xingzhu Ju; Rui Bi; Xiaojun Chen; Wentao Yang; Xiaohua Wu
Journal:  J Ovarian Res       Date:  2017-01-25       Impact factor: 4.234

7.  Low frequency of BRAF and KRAS mutations in Chinese patients with low-grade serous carcinoma of the ovary.

Authors:  Yan Xu; Rui Bi; Yaoxing Xiao; Xiaoyu Tu; Ming Li; Anqi Li; Ling Shan; Shuling Zhou; Wentao Yang
Journal:  Diagn Pathol       Date:  2017-12-22       Impact factor: 2.644

Review 8.  Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma.

Authors:  Mohammad Ezzati; Amer Abdullah; Ahmad Shariftabrizi; June Hou; Michael Kopf; Jennifer K Stedman; Robert Samuelson; Shohreh Shahabi
Journal:  Int Sch Res Notices       Date:  2014-10-29

9.  Gene co-expression network reveals shared modules predictive of stage and grade in serous ovarian cancers.

Authors:  Qian Sun; Haiyue Zhao; Cong Zhang; Ting Hu; Jianli Wu; Xingguang Lin; Danfeng Luo; Changyu Wang; Li Meng; Ling Xi; Kezhen Li; Junbo Hu; Ding Ma; Tao Zhu
Journal:  Oncotarget       Date:  2017-06-27

10.  Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan.

Authors:  Jun-Hyeok Kang; Yen-Ling Lai; Wen-Fang Cheng; Hyun-Soo Kim; Kuan-Ting Kuo; Yu-Li Chen; Yoo-Young Lee
Journal:  Sci Rep       Date:  2020-11-17       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.